Literature DB >> 22669944

Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.

Erica Tiberia1, Julie Turnbull, Tony Wang, Alessandra Ruggieri, Xiao-Chu Zhao, Nela Pencea, Johan Israelian, Yin Wang, Cameron A Ackerley, Peixiang Wang, Yan Liu, Berge A Minassian.   

Abstract

The solubility of glycogen, essential to its metabolism, is a property of its shape, a sphere generated through extensive branching during synthesis. Lafora disease (LD) is a severe teenage-onset neurodegenerative epilepsy and results from multiorgan accumulations, termed Lafora bodies (LB), of abnormally structured aggregation-prone and digestion-resistant glycogen. LD is caused by loss-of-function mutations in the EPM2A or EPM2B gene, encoding the interacting laforin phosphatase and malin E3 ubiquitin ligase enzymes, respectively. The substrate and function of malin are unknown; an early counterintuitive observation in cell culture experiments that it targets laforin to proteasomal degradation was not pursued until now. The substrate and function of laforin have recently been elucidated. Laforin dephosphorylates glycogen during synthesis, without which phosphate ions interfere with and distort glycogen construction, leading to LB. We hypothesized that laforin in excess or not removed following its action on glycogen also interferes with glycogen formation. We show in malin-deficient mice that the absence of malin results in massively increased laforin preceding the appearance of LB and that laforin gradually accumulates in glycogen, which corresponds to progressive LB generation. We show that increasing the amounts of laforin in cell culture causes LB formation and that this occurs only with glycogen binding-competent laforin. In summary, malin deficiency causes increased laforin, increased laforin binding to glycogen, and LB formation. Furthermore, increased levels of laforin, when it can bind glycogen, causes LB. We conclude that malin functions to regulate laforin and that malin deficiency at least in part causes LB and LD through increased laforin binding to glycogen.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22669944      PMCID: PMC3408169          DOI: 10.1074/jbc.M111.331611

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Lack of an alpha-1,4-glucan: alpha-1,4-glucan 6-glycosyl transferase in a case of type IV glycogenosis.

Authors:  B I Brown; D H Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1966-08       Impact factor: 11.205

2.  Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy.

Authors:  Olga Criado; Carmen Aguado; Javier Gayarre; Lara Duran-Trio; Ana M Garcia-Cabrero; Santiago Vernia; Beatriz San Millán; Miguel Heredia; Carlos Romá-Mateo; Silvana Mouron; Lucía Juana-López; Mercedes Domínguez; Carmen Navarro; Jose M Serratosa; Marina Sanchez; Pascual Sanz; Paola Bovolenta; Erwin Knecht; Santiago Rodriguez de Cordoba
Journal:  Hum Mol Genet       Date:  2011-12-20       Impact factor: 6.150

3.  A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.

Authors:  Jianyong Wang; Jeanne A Stuckey; Matthew J Wishart; Jack E Dixon
Journal:  J Biol Chem       Date:  2001-12-05       Impact factor: 5.157

4.  Glycogen synthase localization and activity in rat skeletal muscle is strongly dependent on glycogen content.

Authors:  J N Nielsen; W Derave; S Kristiansen; E Ralston; T Ploug; E A Richter
Journal:  J Physiol       Date:  2001-03-15       Impact factor: 5.182

5.  Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.

Authors:  Subramaniam Ganesh; Antonio V Delgado-Escueta; Toshiro Sakamoto; Maria Rosa Avila; Jesus Machado-Salas; Yoshinobu Hoshii; Takumi Akagi; Hiroshi Gomi; Toshimitsu Suzuki; Kenji Amano; Kishan Lal Agarwala; Yuki Hasegawa; Dong-Sheng Bai; Tokuhiro Ishihara; Tsutomu Hashikawa; Shigeyoshi Itohara; Eain M Cornford; Hiroaki Niki; Kazuhiro Yamakawa
Journal:  Hum Mol Genet       Date:  2002-05-15       Impact factor: 6.150

Review 6.  Glycogen and its metabolism.

Authors:  Peter J Roach
Journal:  Curr Mol Med       Date:  2002-03       Impact factor: 2.222

Review 7.  Functional diversity of protein phosphatase-1, a cellular economizer and reset button.

Authors:  Hugo Ceulemans; Mathieu Bollen
Journal:  Physiol Rev       Date:  2004-01       Impact factor: 37.312

8.  The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies.

Authors:  Subramaniam Ganesh; Naomi Tsurutani; Toshimitsu Suzuki; Yoshinobu Hoshii; Tokuhiro Ishihara; Antonio V Delgado-Escueta; Kazuhiro Yamakawa
Journal:  Biochem Biophys Res Commun       Date:  2004-01-23       Impact factor: 3.575

9.  Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.

Authors:  Maria Elena Fernández-Sánchez; Olga Criado-García; Karen E Heath; Belén García-Fojeda; Iria Medraño-Fernández; Pilar Gomez-Garre; Pascual Sanz; José María Serratosa; Santiago Rodríguez de Córdoba
Journal:  Hum Mol Genet       Date:  2003-10-07       Impact factor: 6.150

10.  Mutations in NHLRC1 cause progressive myoclonus epilepsy.

Authors:  Elayne M Chan; Edwin J Young; Leonarda Ianzano; Iulia Munteanu; Xiaochu Zhao; Constantine C Christopoulos; Giuliano Avanzini; Maurizio Elia; Cameron A Ackerley; Nebojsa J Jovic; Saeed Bohlega; Eva Andermann; Guy A Rouleau; Antonio V Delgado-Escueta; Berge A Minassian; Stephen W Scherer
Journal:  Nat Genet       Date:  2003-09-07       Impact factor: 38.330

View more
  19 in total

1.  Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.

Authors:  M Kathryn Brewer; Annette Uittenbogaard; Grant L Austin; Dyann M Segvich; Anna DePaoli-Roach; Peter J Roach; John J McCarthy; Zoe R Simmons; Jason A Brandon; Zhengqiu Zhou; Jill Zeller; Lyndsay E A Young; Ramon C Sun; James R Pauly; Nadine M Aziz; Bradley L Hodges; Tracy R McKnight; Dustin D Armstrong; Matthew S Gentry
Journal:  Cell Metab       Date:  2019-07-25       Impact factor: 27.287

2.  Skeletal Muscle Glycogen Chain Length Correlates with Insolubility in Mouse Models of Polyglucosan-Associated Neurodegenerative Diseases.

Authors:  Mitchell A Sullivan; Silvia Nitschke; Evan P Skwara; Peixiang Wang; Xiaochu Zhao; Xiao S Pan; Erin E Chown; Travis Wang; Ami M Perri; Jennifer P Y Lee; Francisco Vilaplana; Berge A Minassian; Felix Nitschke
Journal:  Cell Rep       Date:  2019-04-30       Impact factor: 9.423

3.  Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.

Authors:  Yin Wang; Keli Ma; Peixiang Wang; Otto Baba; Helen Zhang; Jack M Parent; Pan Zheng; Yang Liu; Berge A Minassian; Yan Liu
Journal:  Mol Neurobiol       Date:  2013-04-02       Impact factor: 5.590

4.  NHLRC1 repeat expansion in two beagles with Lafora disease.

Authors:  I Hajek; F Kettner; V Simerdova; C Rusbridge; P Wang; B A Minassian; V Palus
Journal:  J Small Anim Pract       Date:  2016-10-16       Impact factor: 1.522

Review 5.  Lafora disease.

Authors:  Julie Turnbull; Erica Tiberia; Pasquale Striano; Pierre Genton; Stirling Carpenter; Cameron A Ackerley; Berge A Minassian
Journal:  Epileptic Disord       Date:  2016-09-01       Impact factor: 1.819

Review 6.  Lafora disease: from genotype to phenotype.

Authors:  Rashmi Parihar; Anupama Rai; Subramaniam Ganesh
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

7.  Polyglucosan body structure in Lafora disease.

Authors:  M Kathryn Brewer; Jean-Luc Putaux; Alberto Rondon; Annette Uittenbogaard; Mitchell A Sullivan; Matthew S Gentry
Journal:  Carbohydr Polym       Date:  2020-04-14       Impact factor: 9.381

8.  A novel mouse model that recapitulates adult-onset glycogenosis type 4.

Authors:  H Orhan Akman; Valentina Emmanuele; Yasemin Gülcan Kurt; Bülent Kurt; Tatiana Sheiko; Salvatore DiMauro; William J Craigen
Journal:  Hum Mol Genet       Date:  2015-09-18       Impact factor: 6.150

Review 9.  Lafora disease - from pathogenesis to treatment strategies.

Authors:  Felix Nitschke; Saija J Ahonen; Silvia Nitschke; Sharmistha Mitra; Berge A Minassian
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

10.  Trehalose Ameliorates Seizure Susceptibility in Lafora Disease Mouse Models by Suppressing Neuroinflammation and Endoplasmic Reticulum Stress.

Authors:  Priyanka Sinha; Bhupender Verma; Subramaniam Ganesh
Journal:  Mol Neurobiol       Date:  2020-10-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.